MGTX

MeiraGTx Holdings plc (MGTX) | Rumor.io

MeiraGTx Holdings

MGTX

Attention (50-day avg)0%

Attention rank (50-day avg)#2,836

Bullish sentiment (50-day avg)69%

Price to earnings ratio13.3

Market capitalization1.1B

Earnings per share0.82

Dividend yield (TTM)—

Revenue (annual)81.4M

Net income (annual)-114.2M

Social

What share of all stock conversation is about MGTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Jul 23

MeiraGTx Holdings plc (MGTX) is experiencing a decline in stock price, with a 2.88% drop to $12.16.
Investors are expressing concerns about holding onto their shares, with some questioning whether to buy the dip or cut losses.
The potential for further decline or a rebound is being debated, with some investors speculating on the possible extent of the drop.

Generated by AI

Sentiment

Of the messages about MGTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	83.33%	77.78% +20.63	92.42% +0.26
Bearish	—	16.67%	22.22% -20.63	7.58% -0.26

Nov 10

MeiraGTx Holdings plc's ($MGTX) recent deal with Eli Lilly could bring in up to $135 million in additional cash upon the achievement of certain development and regulatory approval milestones.
The partnership with Eli Lilly grants the company rights to its experimental gene therapy for a rare, inherited disorder that causes severe vision loss from birth, which could lead to significant revenue opportunities.
The deal with Lilly includes an upfront payment of $75 million, and MeiraGTx has a strong pipeline with multiple deals similar to this one, which could eventually lead to increased visibility and price appreciation for the stock.

Generated by AI

Topics

Of the messages about MGTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	82.77%
Technical Analysis	—	0%	0%	2.38%
Earnings	—	0%	0%	2.38%
Analysts	—	0%	0%	12.28%
Controversies	—	0%	0%	0%
Macro	—	0%	0%	0.2%

Analysts· Jul 3

Barclays initiated coverage on MeiraGTx Holdings plc ($MGTX) with an "Overweight" rating and a price target of $20.
Multiple research firms, including Barclays and BofA/Merrill Lynch, have initiated coverage on MeiraGTx Holdings plc ($MGTX) with buy or overweight ratings.
MeiraGTx Holdings plc ($MGTX) is reaching an inflection point, according to Barclays, which initiated coverage with an "Overweight" rating and a price target of $20.

Announcements· Jul 23

MeiraGTx Holdings plc (MGTX) has seen a significant drop in its stock price, with a decrease of 2.875%.
The market is experiencing pressure, with some investors nervous about holding onto their shares and others considering cutting losses.
The current slide has some investors worried, with questions about whether to buy the dip or cut losses, and others are considering whether to double down or bail.

Generated by AI

Community

Of the messages about MGTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	80.95%	82.05%	57.21%
Newcomers	0%	19.05%	17.95%	42.79%

Regulars· Dec 21

MeiraGTx Holdings plc has announced an asset purchase agreement with Janssen Pharmaceuticals for the remaining interests in bota-vec for the treatment of X-linked Retinitis Pigmentosa, as well as a commercial supply agreement and a technology transfer agreement for bota-vec manufacturing.
The agreement is worth up to $415 million, with MeiraGTx receiving $130 million in upfront and near-term milestone payments.
MeiraGTx owns four valuable assets, including a manufacturing facility worth $400-600 million, two clinical stage programs, and gene silencing technology with a market capitalization of $315 million, in addition to the bota-vec deal.

Newcomers· Jul 23

Many newcomers are worried about the recent decline in MeiraGTx Holdings plc, with some wondering if it's a good time to buy the dip or if they should cut losses.
Some users are unsure about whether to average down their investment or accept the loss, while others are feeling uneasy and unsure about what to do.
There is a general sense of uncertainty among newcomers about MeiraGTx Holdings plc's future, with some wondering if the decline is a value play or a trap, and others feeling shaky and unsure about whether to buy the dip or exit.

Generated by AI

News

Bank of America Securities Remains a Buy on Meiragtx Holdings (MGTX)

Detailed price information for Meiragtx Holdings Plc (MGTX-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

What Could MeiraGTx Holdings (MGTX) New Hires And Profit Swing Signal?

MeiraGTx Holdings (NasdaqGS:MGTX) announced two senior leadership appointments, adding executives with extensive global pharmaceutical development and manufacturing experience. The company reported a turnaround in second quarter financial performance, shifting from prior net losses to profitability. Management indicated that these leadership changes and financial results could affect MeiraGTx's pipeline progress and commercialization plans. Consider taking a broader look at related...

1mo agoYahoo Finance

Also Discussed

Investors talking about MGTX also mention

#	Name	Attention
1	Mirum Pharmaceuticals, Inc.MIRM	0%0
2	Denali Therapeutics Inc.DNLI	0%new
3	4D Molecular Therapeutics, Inc.FDMT	0%new
4	Regenxbio Inc.RGNX	0%+0
5	UFP Technologies Inc.UFPT	0%0
6	BioAge Labs, Inc.BIOA	0.01%+0
7	Insight Enterprises, Inc.NSIT	0%0
8	Themes US Cash Flow Champions ETFLGCF	0%new
9	Standex International CorporationSXI	0%new
10	Nurix Therapeutics, Inc.NRIX	0%new

MeiraGTx Holdings plc

Healthcare
Biotechnology

MeiraGTx Holdings plc is a clinical-stage genetic medicines company focused on developing gene and cell therapies for serious inherited and acquired diseases. MeiraGTx Holdings plc uses a vertically integrated model that combines discovery, development, and manufacturing capabilities to support its genetic medicine programs. Its current pipeline targets conditions in the eye, salivary gland, and central nervous system, including retinal disorders, radiation-induced xerostomia, and Parkinson’s disease. The company’s work centers on local delivery of small doses designed to produce disease-modifying effects in areas of high unmet medical need. MeiraGTx Holdings plc operates as part of the biotechnology and health technology market, where it contributes to the advancement of precision therapies built around genetic intervention.

Website

Location

655 Third Avenue

New York, NY, 10017

United States

Social

What share of all stock conversation is about MGTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Jul 23

MeiraGTx Holdings plc (MGTX) is experiencing a decline in stock price, with a 2.88% drop to $12.16.
Investors are expressing concerns about holding onto their shares, with some questioning whether to buy the dip or cut losses.
The potential for further decline or a rebound is being debated, with some investors speculating on the possible extent of the drop.

Generated by AI

Sentiment

Of the messages about MGTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	83.33%	77.78% +20.63	92.42% +0.26
Bearish	—	16.67%	22.22% -20.63	7.58% -0.26

Nov 10

MeiraGTx Holdings plc's ($MGTX) recent deal with Eli Lilly could bring in up to $135 million in additional cash upon the achievement of certain development and regulatory approval milestones.
The partnership with Eli Lilly grants the company rights to its experimental gene therapy for a rare, inherited disorder that causes severe vision loss from birth, which could lead to significant revenue opportunities.
The deal with Lilly includes an upfront payment of $75 million, and MeiraGTx has a strong pipeline with multiple deals similar to this one, which could eventually lead to increased visibility and price appreciation for the stock.

Generated by AI

Topics

Of the messages about MGTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	82.77%
Technical Analysis	—	0%	0%	2.38%
Earnings	—	0%	0%	2.38%
Analysts	—	0%	0%	12.28%
Controversies	—	0%	0%	0%
Macro	—	0%	0%	0.2%

Analysts· Jul 3

Barclays initiated coverage on MeiraGTx Holdings plc ($MGTX) with an "Overweight" rating and a price target of $20.
Multiple research firms, including Barclays and BofA/Merrill Lynch, have initiated coverage on MeiraGTx Holdings plc ($MGTX) with buy or overweight ratings.
MeiraGTx Holdings plc ($MGTX) is reaching an inflection point, according to Barclays, which initiated coverage with an "Overweight" rating and a price target of $20.

Announcements· Jul 23

MeiraGTx Holdings plc (MGTX) has seen a significant drop in its stock price, with a decrease of 2.875%.
The market is experiencing pressure, with some investors nervous about holding onto their shares and others considering cutting losses.
The current slide has some investors worried, with questions about whether to buy the dip or cut losses, and others are considering whether to double down or bail.

Generated by AI

Community

Of the messages about MGTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	80.95%	82.05%	57.21%
Newcomers	0%	19.05%	17.95%	42.79%

Regulars· Dec 21

MeiraGTx Holdings plc has announced an asset purchase agreement with Janssen Pharmaceuticals for the remaining interests in bota-vec for the treatment of X-linked Retinitis Pigmentosa, as well as a commercial supply agreement and a technology transfer agreement for bota-vec manufacturing.
The agreement is worth up to $415 million, with MeiraGTx receiving $130 million in upfront and near-term milestone payments.
MeiraGTx owns four valuable assets, including a manufacturing facility worth $400-600 million, two clinical stage programs, and gene silencing technology with a market capitalization of $315 million, in addition to the bota-vec deal.

Newcomers· Jul 23

Many newcomers are worried about the recent decline in MeiraGTx Holdings plc, with some wondering if it's a good time to buy the dip or if they should cut losses.
Some users are unsure about whether to average down their investment or accept the loss, while others are feeling uneasy and unsure about what to do.
There is a general sense of uncertainty among newcomers about MeiraGTx Holdings plc's future, with some wondering if the decline is a value play or a trap, and others feeling shaky and unsure about whether to buy the dip or exit.

Generated by AI

MeiraGTx Holdings

Social

Jul 23

Nov 10

Analysts· Jul 3

Announcements· Jul 23

Regulars· Dec 21

Newcomers· Jul 23

Goldman Sachs initiates MeiraGTx stock coverage with neutral rating

Raymond James stays bullish on Meiragtx stock after rival data

MeiraGTx appoints Alan Sebulsky to board of directors

Meiragtx CEO Forbes sells $859,320 in company stock

Bank of America Securities Remains a Buy on Meiragtx Holdings (MGTX)

What Could MeiraGTx Holdings (MGTX) New Hires And Profit Swing Signal?

Also Discussed

MeiraGTx Holdings plc

Company Information

Location

Goldman Sachs initiates MeiraGTx stock coverage with neutral rating

Raymond James stays bullish on Meiragtx stock after rival data

MeiraGTx appoints Alan Sebulsky to board of directors

Meiragtx CEO Forbes sells $859,320 in company stock

Bank of America Securities Remains a Buy on Meiragtx Holdings (MGTX)

What Could MeiraGTx Holdings (MGTX) New Hires And Profit Swing Signal?

Also Discussed

Social

Jul 23

Nov 10

Analysts· Jul 3

Announcements· Jul 23

Regulars· Dec 21

Newcomers· Jul 23